MedDataX Logo

Pazopanib Maintenance for SCLC

NCT ID: NCT01797874

Last Updated: 2019-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SCLC

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pazopanib maintenance efficacy SCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pazopanib

pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC

Group Type EXPERIMENTAL

Pazopanib

Intervention Type DRUG

Experimental

placebo

placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pazopanib

Experimental

Intervention Type DRUG

Placebo

placebo arm

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Votrient

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed SCLC
* no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
* history of 4 cycles of etoposide/platinum 1st-line therapy
* between 21 days and 42 days since C4D1 of etoposide/platinum
* no symptomatic brain meta

Exclusion Criteria

* poor hepatic, renal function
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Samsung Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Myung-Ju Ahn

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samsung Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-09-060-002

Identifier Type: -

Identifier Source: org_study_id